Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Breast Neoplasms 145Lymphoma 104Lymphoma, Large B-Cell, Diffuse 76Sarcoma 62Hodgkin Disease 46Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Burkitt Lymphoma 35Triple Negative Breast Neoplasms 31Lymphoma, Non-Hodgkin 29Lymphoma, Mantle-Cell 27Leukemia 25Neoplasms 22Lymphoma, Follicular 22Neoplasm Metastasis 21Multiple Myeloma 21Neuroblastoma 20Carcinoma, Hepatocellular 18Ovarian Neoplasms 16Lymphoma, B-Cell 16Liver Neoplasms 14Urinary Bladder Neoplasms 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Osteosarcoma 12Lymphoma, T-Cell, Peripheral 11Lymphoma, Large-Cell, Anaplastic 11Inflammatory Breast Neoplasms 11Breast Neoplasms, Male 11Prostatic Neoplasms 10Dendritic Cell Sarcoma, Interdigitating 10Lymphoma, Large-Cell, Immunoblastic 9

Interventions

Cyclophosphamide 7fludarabine phosphate 4Tacrolimus 4Mycophenolic Acid 4Busulfan 4pembrolizumab 2fludarabine 2cobomarsen 2Whole-Body Irradiation 2Vincristine 2Rituximab 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Melphalan 2Doxorubicin 2thymoglobulin 1Vorinostat 1Plasmalyte A 1Ifosfamide 1Etoposide 1Dimethyl Sulfoxide 1Carboplatin 1Brentuximab Vedotin 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Immune System Diseases × Doxorubicin × Clear all
NCT02855359 2019-03-11

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Seagen Inc.

Phase 2 Terminated
24 enrolled 10 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00365274 2014-06-02

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 3 charts
Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡